Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials

Willemien F J Hof, Jan Freark de Boer, Henkjan J Verkade*

*Bijbehorende auteur voor dit werk

Onderzoeksoutputpeer review

Samenvatting

INTRODUCTION: Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injury. Until recently, no approved treatments were available for these patients.

AREAS COVERED: Recent clinical trials for PFIC treatment have focused on intestine-restricted ileal bile acid transporter (IBAT) inhibitors. These compounds aim to reduce the pool size of bile acids by interrupting their enterohepatic circulation. Other emerging treatments in the pipeline include systemic IBAT inhibitors, synthetic bile acid derivatives, compounds targeting bile acid synthesis via the FXR/FGF axis, and chaperones/potentiators that aim to enhance the residual activity of the mutated transporters.

EXPERT OPINION: Substantial progress has been made in drug development for PFIC patients during the last couple of years. Although data concerning long-term efficacy are as yet only scarcely available, new therapies have demonstrated robust efficacy in a considerable fraction of patients at least on the shorter term. However, a substantial fraction of PFIC patients does not respond to these novel therapies and thus still requires surgical treatment, including liver transplantation before adulthood. Hence, there is still an unmet medical for long-term effective medical, preferably non-surgical, treatment for all PFIC patients.

Originele taal-2English
TijdschriftExpert Opinion on Emerging Drugs
DOI's
StatusE-pub ahead of print - 4-apr.-2024

Vingerafdruk

Duik in de onderzoeksthema's van 'Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials'. Samen vormen ze een unieke vingerafdruk.

Citeer dit